Large epidemiological studies have demonstrated that people with HIV carry an increasing burden of metabolic comorbidities. Older antiretroviral therapy has been associated with many of these comorbidities, and as the HIV population ages, the risk for metabolic comorbidities increases. Studies that specifically explore the metabolic effects of contemporary antiretroviral therapy are needed.
In this issue, Dr. Suman Srinivasa and nurse practitioner Kathleen Fitch from Harvard Medical School review key studies evaluating the effects of contemporary antiretroviral therapy on the metabolic complications common in people with HIV, including bone disease, cardiovascular disease, weight gain, and liver disease.
Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: October 26, 2018
Expiration date: October 25, 2020